{"id":782646,"date":"2023-09-07T17:39:11","date_gmt":"2023-09-07T21:39:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"},"modified":"2023-09-07T17:39:11","modified_gmt":"2023-09-07T21:39:11","slug":"voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","title":{"rendered":"Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., Sept.  07, 2023  (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with three newly-hired employees that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees\u2019 entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager\u2019s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option awards to two of these employees became effective on September 5, 2023, and the option award to the third employee became effective on September 6, 2023. The restricted stock unit award to each employee is scheduled to become effective on October 1, 2023.<\/p>\n<p>The stock option award to two employees provides for the purchase of an aggregate of 90,000 shares of Voyager\u2019s common stock, and the restricted stock unit award to such employees will represent 45,000 shares of Voyager\u2019s common stock. The stock option award to the third employee provides for the purchase of an aggregate of 44,000 shares of Voyager\u2019s common stock, and the restricted stock unit award to such employee will represent 22,000 shares of Voyager\u2019s common stock. Each stock option has a ten-year term. The stock option awards to the two employees have an exercise price of $9.26 per share, which is equal to the closing price of Voyager&#8217;s common stock on September 5, 2023, the effective date of grant. The stock option to the third employee has an exercise price of $9.39 per share, which is equal to the closing price of Voyager&#8217;s common stock on September 6, 2023, the effective date of grant. Each stock option vests over four years, with 25% of the shares underlying the stock option vesting on the first anniversary of the effective date of grant and 75% of the shares underlying the stock option vesting in 36 equal monthly installments following the first anniversary of the effective date of grant. Each restricted stock unit award vests annually in equal installments over three years, beginning on the first anniversary of the effective date of grant. Vesting of each employee\u2019s equity awards is subject to such employee\u2019s continued employment with Voyager. Each equity award is also subject to the terms and conditions of an award agreement.<\/p>\n<p>\n        <strong>About\u202fVoyager Therapeutics<\/strong>\u00a0<br \/>Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager\u2019s TRACER\u2122 AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Pfizer Inc., Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager\u2019s own pipeline. Voyager\u2019s pipeline includes wholly owned and collaborative preclinical programs in Alzheimer\u2019s disease, amyotrophic lateral sclerosis (ALS), Parkinson\u2019s disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CCBSRPkSlZoj4YiOH2Jyaka5oEVx80cOJdIDsLIxGz5O1F9CWyATp4LJX36qM-Q45svNVToPyn84S-vZy34-xxMfrBu45WsVkUVU3QR-Wa6NGvgPEvD9zQ5OO49Bm8MdBNshqTbHfRewlUzF_VMu7WWS9ChXFxvgm9lWytzx_bvWxggBLRtr2jpuUvPkuC30vF6zdEuSB7KqU8wMpXCDssGqclpSQqAI3aa1UUCb8SdRyyYluXilrJI3LfoRRM4CQMAXqx9WCdaHi0Z8RnrlGIuFdwaU7klEBaHHNGVNkls=\" rel=\"nofollow noopener\" target=\"_blank\">www.voyagertherapeutics.com<\/a>.<\/p>\n<p>\n        <em>Voyager Therapeutics<\/em><br \/>\n        <sup><br \/>\n          <em>\u00ae<\/em><br \/>\n        <\/sup><br \/>\n        <em>\u00a0is a registered trademark, and TRACER\u2122 is a trademark, of\u00a0Voyager Therapeutics, Inc.<\/em><br \/>\n        \n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l-M7jkVxp4RVUzUKLUcyqJT9HCZNQPrZ81clLKhZND6qua2zw7eMsPt5Xqw87UOCiMC7CDo9m06RXZPwAUyXsrsx7fhnW-krKRowgORkeQU=\" rel=\"nofollow noopener\" target=\"_blank\">Investors@vygr.com<\/a>\u00a0\u00a0<\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Peg Rusconi<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ozf2y9HoSr2cgkSjzMDjcOLq720LrioJHQPn7yxWxqCEtEiUMBeWGsxnqb9Ez9OWDjTD8w-eyVUP2SXk_1cL8ZbHi64PIwNNdhPl8iNSPBviUU8X9fSlUDuYZCF4_x81\" rel=\"nofollow noopener\" target=\"_blank\">prusconi@vergescientific.com<\/a>\u00a0<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODU3OCM1ODA0MTg2IzIwMTg4NDA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ODc4NWJlOGQtYzlkNi00MzlkLTkzZGItZTI5MDcyZjU4NmQwLTEwMzA0MTM=\/tiny\/Voyager-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with three newly-hired employees that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees\u2019 entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager\u2019s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option awards to two of these employees became effective on September 5, 2023, and the option award to the third employee became effective on September 6, 2023. The restricted stock unit &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-782646","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with three newly-hired employees that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees\u2019 entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager\u2019s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option awards to two of these employees became effective on September 5, 2023, and the option award to the third employee became effective on September 6, 2023. The restricted stock unit &hellip; Continue reading &quot;Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-07T21:39:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODU3OCM1ODA0MTg2IzIwMTg4NDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2023-09-07T21:39:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\"},\"wordCount\":578,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODU3OCM1ODA0MTg2IzIwMTg4NDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\",\"name\":\"Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODU3OCM1ODA0MTg2IzIwMTg4NDA=\",\"datePublished\":\"2023-09-07T21:39:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODU3OCM1ODA0MTg2IzIwMTg4NDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODU3OCM1ODA0MTg2IzIwMTg4NDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","og_locale":"en_US","og_type":"article","og_title":"Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with three newly-hired employees that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees\u2019 entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager\u2019s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option awards to two of these employees became effective on September 5, 2023, and the option award to the third employee became effective on September 6, 2023. The restricted stock unit &hellip; Continue reading \"Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-07T21:39:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODU3OCM1ODA0MTg2IzIwMTg4NDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2023-09-07T21:39:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"},"wordCount":578,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODU3OCM1ODA0MTg2IzIwMTg4NDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","name":"Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODU3OCM1ODA0MTg2IzIwMTg4NDA=","datePublished":"2023-09-07T21:39:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODU3OCM1ODA0MTg2IzIwMTg4NDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODU3OCM1ODA0MTg2IzIwMTg4NDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=782646"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782646\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=782646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=782646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=782646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}